Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431–2442.
317.
Le T, Leis A, Pahwa P, et al. Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment. Gynecol Oncol 2004;92:839–844.
318.
Alvarez AA, Krigman HR, Whitaker RS, et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res.1999;5:587–591.
319.
Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165–5171.
320.
Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76– 82.
321.
Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180–5186 [Erratum in: J Clin Oncol 2008;26:1773].
322.
Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007;107:118–123.
323.
Moroney JW, Sood AK, Coleman RL. Aﬂibercept in epithelial ovarian carcinoma [review]. Future Oncol 2009;5:591–600.
324.
Hacker NF, Berek JS, Burnison CM, et al. Whole abdominal radiation as salvage therapy for epithelial ovarian cancer. Obstet Gynecol 1985;65:60–66.
325.
Castaldo TW, Petrilli ES, Ballon SC, et al. Intestinal operations in patients with ovarian carcinoma. Am J Obstet Gynecol 1981;139:80– 84.
326.
Krebs HB, Goplerud DR. Surgical management of bowel obstruction in advanced ovarian cancer. Obstet Gynecol 1983;61:327–330.
327.
Tunca JC, Buchler DA, Mack EA, et al. The management of ovarian cancer caused bowel obstruction. Gynecol Oncol 1981;12:186–192.
328.
Piver MS, Barlow JJ, Lele SB, et al. Survival after ovarian cancer induced intestinal obstruction. Gynecol Oncol 1982;13:44–49.
329.
Clarke-Pearson DL, DeLong ER, Chin N, et al. Intestinal obstruction in patients with ovarian cancer: variables associated with surgical complications and survival. Arch Surg 1988;123:42–45.
330.